Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

NVS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings
Logo
  • Home
  • AI Agent
  • Annotations
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

NVS US​
HomeStock ScreenerDocument SearchChartingWatchlistsRecent Filings

Novartis Ag Sponsored ADR(NVS US)

$160.50+0.250.16%Ext:$161.36+0.860.54%(After Hours · 00:13:35 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Novartis Ag Sponsored ADR(NVS US)

$160.50+0.250.16%Ext:$161.36+0.860.54%(After Hours · 00:13:35 UTC)
Ask AI
Doc SearchProfileEntity StructureFinancialsChartingShort InterestEmployees

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Financials & Metrics

FinancialsChartingShort InterestEmployees

Novartis Ag Sponsored ADR — Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Vasant Narasimhan
Headquarters
Basel, V8, CH
IPO Date
Nov 7, 1996
Employees
75,267
Website
www.novartis.com

Key Metrics

Price
$141.00
Market Cap
$268.00B
Revenue (TTM)
$13.52B
Net Income (TTM)
$3.16B
EPS (TTM)
1.65
P/E (TTM)
19.80
P/B (TTM)
6.96
Dividend Yield
3.04%
ROE (TTM)
8.19%
ROA (TTM)
2.66%
Operating Margin
31.31%
Beta
0.32

Dividends

Last Dividend
$4.74
Last Yield
0.03%

Summary

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Website
www.novartis.com
Location
Basel, V8, CH
Phone41 61 324 1111
Employees75,267
CEOVasant Narasimhan
Sector
Health Care
Industry
Pharmaceuticals
IPO DateNov 7, 1996

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.4K)

Expand
  • 6-KCurrent report (foreign private issuer)12 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))10 Nov
  • FWPFree writing prospectus9 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))9 Nov
  • Form 144Bulto Carulla Victor28 Oct
  • SC 13G/ANOVARTIS AG27 Oct
  • 6-KCurrent report (foreign private issuer)27 Oct
  • 6-KCurrent report (foreign private issuer)8 Sep
  • 6-KCurrent report (foreign private issuer)4 Sep
  • 6-KCurrent report (foreign private issuer)1 Sep
  • 6-KCurrent report (foreign private issuer)21 Jul
  • 6-KCurrent report (foreign private issuer)11 Jun
  • Form 144Bulto Carulla Victor30 Apr
  • 6-KCurrent report (foreign private issuer)28 Apr
  • 6-KCurrent report (foreign private issuer)18 Mar
  • 424B5Prospectus filing (Rule 424(b)(5))17 Mar
  • FWPFree writing prospectus16 Mar
  • 424B5Prospectus filing (Rule 424(b)(5))16 Mar
  • Form 144Marshall Fiona12 Feb
  • Form 144Bulto Carulla Victor9 Feb

News

  • Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice12 Nov
  • Commonwealth Equity Services LLC Purchases 3,997 Shares of Novartis AG $NVS10 Nov
  • 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 20269 Nov
  • Novartis: 3 Key Takeaways for Long-Term Investors3 Nov
  • 3 Stocks to Watch Following Guidance Upgrades2 Nov
  • BioArctic collaborator Novartis terminates agreement2 Nov
  • 6 dividend stocks for investors who want to cut their exposure to the S&P 5002 Nov
  • Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target2 Nov
  • Companies promised AI gains— here's how the payoff showed up in earnings1 Nov
  • Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach31 Oct
  • All You Need to Know About Novartis (NVS) Rating Upgrade to Buy30 Oct
  • Why Novartis (NVS) is a Top Momentum Stock for the Long-Term30 Oct
  • A pharma giant is moving past one patent cliff — but another is already looming30 Oct
  • Novartis AG (NVS) Q3 2026 Earnings Call Transcript29 Oct
  • These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar28 Oct
  • What Novartis (NVS) Said on Its Q3 Earnings Call27 Oct
  • 4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential27 Oct
  • NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss27 Oct
  • Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit27 Oct
  • Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates27 Oct

Mentions in Filings

  • Prior to the acquisition of Marea by the Company, Marea entered into a License Agreement with <strong>Novartis</strong> Pharma AG (“Novartis Agreement”) in May 2022, under which Marea was granted an exclusive worldwide license under certain patent rights, to develop, manufacture, and commercialize a licensed compound for therapeutic areas in endocrinology and metabolic diseases. Marea is obligated to use commercially reasonable efforts to develop and commercializ …
    LISATA THERAPEUTICS, INC.Novartis Ag Sponsored ADR·10-Q - Quarterly report Q3·Q3 26·04:05PM
  • … monia product specifically, we face competition from providers of Rb-82, a competing cardiac perfusion imaging agent manufactured commercially by Bracco and Jubilant Radiopharma. For Ga-68 Gozetotide, competitors include <strong>Novartis</strong> and Telix Pharmaceuticals. For PSMA PET diagnostics, several companies — including Telix Pharmaceuticals, Lantheus, Novartis, and Blue Earth Diagnostics (a Bracco company) — have received FDA approvals for competing PSMA …
    Ionetix Corp / DE /Novartis Ag Sponsored ADR·10-Q - QUARTERLY REPORT Q3·Q3 26·02:29PM
  • … companies, specialized biotechnology companies and emerging biotechnology companies. In IgA nephropathy (“IgAN”), competitors include Biogen Inc., Biohaven, Ltd., Boulevard Bio, Inc., Calliditas Therapeutics AB, Climb Bio, Inc., <strong>Novartis AG</strong>, Otsuka Pharmaceutical Co., Ltd., Roche, Takeda Pharmaceutical Company Limited, Travere Therapeutics, Inc., Vera Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated. In dermatomyositis (“DM”), 45 ---
    Jade Biosciences, Inc.Novartis Ag Sponsored ADR·10-Q - Quarterly report Q3·Q3 26·07:29AM
  • … cardiac PET isotope providers in the U.S. include Bracco and Jubilant Radiopharma, who manufacture Rb-82, which competes with our N-13 product. Similarly, several drug companies have FDA approvals to offer PSMA PET diagnostic drugs including Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., <strong>Novartis AG</strong> and Blue Earth Diagnostics Ltd. (a Bracco Company). Some of these companies, in turn, outsource the production of their isotopes to others.
    Ionetix Corp / DE /Novartis Ag Sponsored ADR·424B3 - PROSPECTUS·Q4 26·07:18AM
  • … ducts included: AbbVie (Vyalev, Botox, Qulipta, Ubrelvy, Vraylar, Juvmo, Duodopa); Johnson & Johnson (Invega Sustenna, Spravato, Caplyta, Concerta); Roche (Ocrevus, Evrysdi, Fenebrutinib, Enspryng, Madopar, Trontinemab); <strong>Novartis</strong> (Kesimpta, Zolgensma, Aimovig, Rhapsido, Mayzent, Gilenya); Teva (Austedo, Ajovy, Uzedy, Copaxone, Olanzapine (LAI)); Eli Lilly (Kisunla, Emgality, Remternetug, Prozac); Eisai (Leqembi, Dayvigo, Aricept, Fycompa, Methyco …
    Praxis Precision Medicines, Inc.Novartis Ag Sponsored ADR·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·12 Nov
  • … 5. Prior to that, Mr. Sherman served as President, Chief Executive Officer, and member of the board of directors of Endocyte, Inc., a biopharmaceutical company, from June 2016 until December 2018, when it was acquired by <strong>Novartis</strong>. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive rol …
    Werewolf Therapeutics, Inc.Novartis Ag Sponsored ADR·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov

Key Stats

Trading

Px/Chg 1D$141.00 / -0.04%
Prev Close$153.81
% of 52Wk H89.21%
Avg Volume1.97M
Beta0.32
Mkt Cap268.00B
FD Mkt Cap289.02B

Float

Shrs Out/Float1.90B / 1.83B
Short Float0.00%
Days to Cover1.95
Stock Repurchased$1.88B

Current Valuation

EV308.54B
EV/EBITDA13.77
EV/Sales5.50
P/B6.96
P/S4.78
FCF Yield1.07%
ROE8.19%
ROA2.66%
Current Ratio0.85

Dividend

Cash$4.74
Yield3.04%
Yield (TTM)3.04%

Estimates

P/E19.80
Est P/E0.00
Est EPS2.11
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings51.8327.1813.5319.03114.5184.92
Price / Sales10.714.354.314.3920.6919.82
Price / Book Value5.123.194.305.165.986.96
Price / Free Cash Flow62.1415.7617.1616.46167.9193.41
ENTERPRISE VALUE METRICS
Enterprise Value256,193.5209,494.1213,926.3247,077.0301,933.5308,536.8
Enterprise Value / Sales11.934.824.584.7822.6422.81
Enterprise Value / EBITDA30.8914.2711.7211.9359.5257.03
Enterprise Value / EBIT44.8226.2621.4416.8785.7373.78

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue5.7%43,974.043,461.046,660.051,722.054,811.3
Gross Income6.3%32,239.031,879.034,188.038,895.041,121.5
EBITDA-7.1%30,914.014,682.018,255.020,715.022,987.1
EBIT-8.6%25,317.07,977.09,978.014,646.017,634.8
Net Income-12.5%24,021.06,955.014,850.011,941.014,055.6
EPS (Diluted)-9.3%10.633.177.105.877.19
BALANCE SHEET
Cash & ST Inv-19.9%28,113.018,615.013,962.013,351.011,590.0
Total Assets-3.2%131,795.0117,453.099,945.0102,246.0115,569.2
Total Liabilities1.9%63,973.058,030.053,195.058,120.069,020.1
Total Shareholder Equity-9.1%67,655.059,342.046,667.044,046.046,130.1
CASH FLOW
Net Operating Cash Flow6.3%15,071.014,236.014,458.017,619.019,242.0
Cap Ex-11.7%-2,556.0-2,239.0-2,753.0-3,814.0-1,555.9
Free Cash Flow9%12,515.011,997.011,705.013,805.017,686.1

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)160.19
Basic Shares1,900.71
Market Cap304,476.1
Diluted Shares1,905.00
Fully Diluted Shares Outstanding1,905.00
Fully Diluted Market Cap305,162.5
+Consolidated Debt48,310.0
−In-the-Money Convertible Debt—
+Capital Leases1,961.0
+Operating Leases—
−Cash & Equivalents-8,870.0
−Short-term Investments-105.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest336.0
+Pension Liabilities—
Enterprise Value344,252.1

Segment data

Revenue

by Products and services

  • Top 20 Products74%
  • Rest Of Portfolio21%
  • Total Anti-infectives Net Sales3%
  • Anti Infectives Sold Under Sandoz Name2%

Revenue

by Geography

  • Other Countries40%
  • United States35%
  • Germany8%
  • China6%
  • France4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US

Novartis Ag Sponsored ADR — Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Sector
Health Care
Industry
Pharmaceuticals
Exchange
UN
CEO
Vasant Narasimhan
Headquarters
Basel, V8, CH
IPO Date
Nov 7, 1996
Employees
75,267
Website
www.novartis.com

Key Metrics

Price
$141.00
Market Cap
$268.00B
Revenue (TTM)
$13.52B
Net Income (TTM)
$3.16B
EPS (TTM)
1.65
P/E (TTM)
19.80
P/B (TTM)
6.96
Dividend Yield
3.04%
ROE (TTM)
8.19%
ROA (TTM)
2.66%
Operating Margin
31.31%
Beta
0.32

Dividends

Last Dividend
$4.74
Last Yield
0.03%

Summary

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Website
www.novartis.com
Location
Basel, V8, CH
Phone41 61 324 1111
Employees75,267
CEOVasant Narasimhan
Sector
Health Care
Industry
Pharmaceuticals
IPO DateNov 7, 1996

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.
How it makes money
A short diagram of the business model.

Latest Documents

SEC Filings(1.4K)

Expand
  • 6-KCurrent report (foreign private issuer)12 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))10 Nov
  • FWPFree writing prospectus9 Nov
  • 424B5Prospectus filing (Rule 424(b)(5))9 Nov
  • Form 144Bulto Carulla Victor28 Oct
  • SC 13G/ANOVARTIS AG27 Oct
  • 6-KCurrent report (foreign private issuer)27 Oct
  • 6-KCurrent report (foreign private issuer)8 Sep
  • 6-KCurrent report (foreign private issuer)4 Sep
  • 6-KCurrent report (foreign private issuer)1 Sep
  • 6-KCurrent report (foreign private issuer)21 Jul
  • 6-KCurrent report (foreign private issuer)11 Jun
  • Form 144Bulto Carulla Victor30 Apr
  • 6-KCurrent report (foreign private issuer)28 Apr
  • 6-KCurrent report (foreign private issuer)18 Mar
  • 424B5Prospectus filing (Rule 424(b)(5))17 Mar
  • FWPFree writing prospectus16 Mar
  • 424B5Prospectus filing (Rule 424(b)(5))16 Mar
  • Form 144Marshall Fiona12 Feb
  • Form 144Bulto Carulla Victor9 Feb

News

  • Are You Looking for a Top Momentum Pick? Why Novartis (NVS) is a Great Choice12 Nov
  • Commonwealth Equity Services LLC Purchases 3,997 Shares of Novartis AG $NVS10 Nov
  • 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 20269 Nov
  • Novartis: 3 Key Takeaways for Long-Term Investors3 Nov
  • 3 Stocks to Watch Following Guidance Upgrades2 Nov
  • BioArctic collaborator Novartis terminates agreement2 Nov
  • 6 dividend stocks for investors who want to cut their exposure to the S&P 5002 Nov
  • Novartis heart drug failure leaves doctors seeking evidence for genetic cholesterol target2 Nov
  • Companies promised AI gains— here's how the payoff showed up in earnings1 Nov
  • Novartis: Q3 2026 Earnings Confirm 'Hold' Recommendation Based On Balanced Approach31 Oct
  • All You Need to Know About Novartis (NVS) Rating Upgrade to Buy30 Oct
  • Why Novartis (NVS) is a Top Momentum Stock for the Long-Term30 Oct
  • A pharma giant is moving past one patent cliff — but another is already looming30 Oct
  • Novartis AG (NVS) Q3 2026 Earnings Call Transcript29 Oct
  • These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar28 Oct
  • What Novartis (NVS) Said on Its Q3 Earnings Call27 Oct
  • 4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential27 Oct
  • NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss27 Oct
  • Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit27 Oct
  • Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates27 Oct

Mentions in Filings

  • Prior to the acquisition of Marea by the Company, Marea entered into a License Agreement with <strong>Novartis</strong> Pharma AG (“Novartis Agreement”) in May 2022, under which Marea was granted an exclusive worldwide license under certain patent rights, to develop, manufacture, and commercialize a licensed compound for therapeutic areas in endocrinology and metabolic diseases. Marea is obligated to use commercially reasonable efforts to develop and commercializ …
    LISATA THERAPEUTICS, INC.Novartis Ag Sponsored ADR·10-Q - Quarterly report Q3·Q3 26·04:05PM
  • … monia product specifically, we face competition from providers of Rb-82, a competing cardiac perfusion imaging agent manufactured commercially by Bracco and Jubilant Radiopharma. For Ga-68 Gozetotide, competitors include <strong>Novartis</strong> and Telix Pharmaceuticals. For PSMA PET diagnostics, several companies — including Telix Pharmaceuticals, Lantheus, Novartis, and Blue Earth Diagnostics (a Bracco company) — have received FDA approvals for competing PSMA …
    Ionetix Corp / DE /Novartis Ag Sponsored ADR·10-Q - QUARTERLY REPORT Q3·Q3 26·02:29PM
  • … companies, specialized biotechnology companies and emerging biotechnology companies. In IgA nephropathy (“IgAN”), competitors include Biogen Inc., Biohaven, Ltd., Boulevard Bio, Inc., Calliditas Therapeutics AB, Climb Bio, Inc., <strong>Novartis AG</strong>, Otsuka Pharmaceutical Co., Ltd., Roche, Takeda Pharmaceutical Company Limited, Travere Therapeutics, Inc., Vera Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated. In dermatomyositis (“DM”), 45 ---
    Jade Biosciences, Inc.Novartis Ag Sponsored ADR·10-Q - Quarterly report Q3·Q3 26·07:29AM
  • … cardiac PET isotope providers in the U.S. include Bracco and Jubilant Radiopharma, who manufacture Rb-82, which competes with our N-13 product. Similarly, several drug companies have FDA approvals to offer PSMA PET diagnostic drugs including Telix Pharmaceuticals Limited, Lantheus Holdings, Inc., <strong>Novartis AG</strong> and Blue Earth Diagnostics Ltd. (a Bracco Company). Some of these companies, in turn, outsource the production of their isotopes to others.
    Ionetix Corp / DE /Novartis Ag Sponsored ADR·424B3 - PROSPECTUS·Q4 26·07:18AM
  • … ducts included: AbbVie (Vyalev, Botox, Qulipta, Ubrelvy, Vraylar, Juvmo, Duodopa); Johnson & Johnson (Invega Sustenna, Spravato, Caplyta, Concerta); Roche (Ocrevus, Evrysdi, Fenebrutinib, Enspryng, Madopar, Trontinemab); <strong>Novartis</strong> (Kesimpta, Zolgensma, Aimovig, Rhapsido, Mayzent, Gilenya); Teva (Austedo, Ajovy, Uzedy, Copaxone, Olanzapine (LAI)); Eli Lilly (Kisunla, Emgality, Remternetug, Prozac); Eisai (Leqembi, Dayvigo, Aricept, Fycompa, Methyco …
    Praxis Precision Medicines, Inc.Novartis Ag Sponsored ADR·EX-99.1 - 8-K - Regulation FD Disclosure·Q4 26·12 Nov
  • … 5. Prior to that, Mr. Sherman served as President, Chief Executive Officer, and member of the board of directors of Endocyte, Inc., a biopharmaceutical company, from June 2016 until December 2018, when it was acquired by <strong>Novartis</strong>. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive rol …
    Werewolf Therapeutics, Inc.Novartis Ag Sponsored ADR·424B3 - Prospectus filing (Rule 424(b)(3))·Q4 26·12 Nov

Key Stats

Trading

Px/Chg 1D$141.00 / -0.04%
Prev Close$153.81
% of 52Wk H89.21%
Avg Volume1.97M
Beta0.32
Mkt Cap268.00B
FD Mkt Cap289.02B

Float

Shrs Out/Float1.90B / 1.83B
Short Float0.00%
Days to Cover1.95
Stock Repurchased$1.88B

Current Valuation

EV308.54B
EV/EBITDA13.77
EV/Sales5.50
P/B6.96
P/S4.78
FCF Yield1.07%
ROE8.19%
ROA2.66%
Current Ratio0.85

Dividend

Cash$4.74
Yield3.04%
Yield (TTM)3.04%

Estimates

P/E19.80
Est P/E0.00
Est EPS2.11
Est PEG0.00

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Apr '26Oct '26
PRICE-BASED RATIOS
Price / Earnings51.8327.1813.5319.03114.5184.92
Price / Sales10.714.354.314.3920.6919.82
Price / Book Value5.123.194.305.165.986.96
Price / Free Cash Flow62.1415.7617.1616.46167.9193.41
ENTERPRISE VALUE METRICS
Enterprise Value256,193.5209,494.1213,926.3247,077.0301,933.5308,536.8
Enterprise Value / Sales11.934.824.584.7822.6422.81
Enterprise Value / EBITDA30.8914.2711.7211.9359.5257.03
Enterprise Value / EBIT44.8226.2621.4416.8785.7373.78

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue5.7%43,974.043,461.046,660.051,722.054,811.3
Gross Income6.3%32,239.031,879.034,188.038,895.041,121.5
EBITDA-7.1%30,914.014,682.018,255.020,715.022,987.1
EBIT-8.6%25,317.07,977.09,978.014,646.017,634.8
Net Income-12.5%24,021.06,955.014,850.011,941.014,055.6
EPS (Diluted)-9.3%10.633.177.105.877.19
BALANCE SHEET
Cash & ST Inv-19.9%28,113.018,615.013,962.013,351.011,590.0
Total Assets-3.2%131,795.0117,453.099,945.0102,246.0115,569.2
Total Liabilities1.9%63,973.058,030.053,195.058,120.069,020.1
Total Shareholder Equity-9.1%67,655.059,342.046,667.044,046.046,130.1
CASH FLOW
Net Operating Cash Flow6.3%15,071.014,236.014,458.017,619.019,242.0
Cap Ex-11.7%-2,556.0-2,239.0-2,753.0-3,814.0-1,555.9
Free Cash Flow9%12,515.011,997.011,705.013,805.017,686.1

Enterprise Value Bridge

Millions USD13 Nov '26
Price (As of 13 Nov '26)160.19
Basic Shares1,900.71
Market Cap304,476.1
Diluted Shares1,905.00
Fully Diluted Shares Outstanding1,905.00
Fully Diluted Market Cap305,162.5
+Consolidated Debt48,310.0
−In-the-Money Convertible Debt—
+Capital Leases1,961.0
+Operating Leases—
−Cash & Equivalents-8,870.0
−Short-term Investments-105.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest336.0
+Pension Liabilities—
Enterprise Value344,252.1

Segment data

Revenue

by Products and services

  • Top 20 Products74%
  • Rest Of Portfolio21%
  • Total Anti-infectives Net Sales3%
  • Anti Infectives Sold Under Sandoz Name2%

Revenue

by Geography

  • Other Countries40%
  • United States35%
  • Germany8%
  • China6%
  • France4%

Related companies

Eli Lilly and Company

LLY US

Johnson & Johnson

JNJ US

AbbVie Inc.

ABBV US

Merck & Co., Inc.

MRK US

Astrazeneca Plc

AZN US

Abbott Laboratories

ABT US

Novo Nordisk A/S

NVO US

Pfizer Inc

PFE US

Vertex Pharmaceuticals Inc / Ma

VRTX US

Bristol Myers Squibb Company

BMY US

Csl Ltd

CSLLY US

Sanofi

SNY US